FINWIRES · TerminalLIVE
FINWIRES

ASX Preview: Australian Shares Set to Fall as Israel-Lebanon Tensions Lift Oil; Lendlease Group Agrees to Sell Development Rights in Italy

By

Australian shares are poised to fall on Monday as oil prices jumped more than 2% after Israel ordered troops deeper into Lebanon, heightening Middle East supply risk and reducing expectations of a near-term easing in regional tensions.

On May 29, the S&P 500 and the Nasdaq Composite each rose 0.2%, while the Dow Jones Industrial Average gained 0.7%.

In the macroeconomy, Australia's manufacturing sector weakened in May as new orders fell sharply for a third consecutive month amid rising costs and ongoing supply-chain disruptions linked to the war in the Middle East, according to a survey by S&P Global published Monday.

Australian card activity growth has slowed sharply in recent months, with non-fuel spending flattening and real consumer activity estimated to be contracting amid inflation and higher fuel costs, according to a Monday report by Westpac Banking (ASX:WBC, NZE:WBC).

In corporate news, Lendlease Group (ASX:LLC) agreed to sell its development rights to the Milano Santa Giulia mixed-use development in Italy to an investment group sponsored by local developer Bizzi & Partners for about AU$250 million.

Ventia Services Group (ASX:VNT, NZE:VNT) secured a five-year, AU$133 million contract extension to continue operating and managing the Australian marine complex-common user facility in Western Australia, with the new term commencing in July 2027.

Australia's benchmark index rose 1.6% or 138.8 points to close at 8,731.70 on May 29.

Related Articles

Asia

Genrix Grants CQ Pharmaceutical Distribution Rights for Myeloma Drug in China, Hong Kong, Macau, Taiwan

Chongqing Genrix Biopharmaceutical (SHA:688443) granted C.Q. Pharmaceutical (SHE:000950) subsidiary Yaoyou Pharmaceutical exclusive development and distribution rights for the GR1803 drug across China and Hong Kong, Macau, and Taiwan.The agreement covers development such as clinical trials, research, and manufacturing, as well as sales, the filing said.The GR1803 velitumimumab drug is indicated for multiple myeloma, a rare form of blood cancer.Yaoyou will pay Genrix up to 600 million yuan in initial payment, listing milestone, and technology transfer milestone payments.Genrix will also be eligible to receive sales royalties of up to a minimum percentage of two digits.

SHA:688443SHE:000950
Asia

Xuan Wu Cloud's CFO Steps Down

Xuan Wu Cloud Technology's (HKG:2392) Chief Financial Officer Ge Ping resigned to devote more time to personal affairs effective May 31, according to a Friday Hong Kong bourse filing.

HKG:2392
Asia

Update: Xi'an Eswin Materials Technology to Invest Up to 40 Million Yuan in Glassmaker's Funding Round

Xi'an Eswin Materials Technology (SHA:688783) will invest up to 40 million yuan in a pre-A+ funding round for Zhuhai Yiyuan Technology, according to a Friday filing with the Shanghai bourse.Zhuhai Yiyuan Technology seeks to raise between 100 million yuan and 200 million yuan in a funding round.The glass manufacturer plans to use the proceeds for capacity expansion, equipment procurement, and technology upgrades.

SHA:688783